There has been an increased prevalence of leprosy after receiving the COVID-19 vaccine, with 49 of 52 people – 98 per cent – transferred to the Leprosy Specialist Clinic at the London Hospital for Tropical Diseases (HTD) in 2021 after the vaccine.
HTD conducted two case studies of people who met the definition of an adverse reaction involving leprosy, whereby within 12 weeks of receiving the vaccine someone developed the disease even though they did not have previous diagnoses or connections. One individual developed “borderline tuberculoid leprosy” one week after the second shot and the other two months after the dose of the COVID-19 vaccine.
English 
Español de Venezuela